The novel interleukin-17AA targeted molecule izokibep showed ACR50 response rates of more than 50% in psoriatic arthritis at 52 weeks, according to data presented at EULAR 2026 Congress.
“What I am going to be commenting on is not so much a novel target, but a very novel construct of a molecular entity for inhibiting IL-17AA,” said Philip J. Mease, MD, of Providence Swedish Medical Center and the University of Washington School of Medicine, in Seattle.
Izokibep (Affibody) is “a unique entity,” according to Mease.
“It is a small molecular biologic,” he said. “It